Benzodiazepines (Psy and mixed indications) updated on 02-10-2025

Club foot / Talipes equinovarus

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S15464
R63605
Blotière - Clonazepam (Other indications), 2019 Talipes equinovarus 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No BZD Coexposure: No (among antiseizure medications) 1.14 [0.16;8.12] C 1/980   1,677/1,875,733 1,678 980
ref
S15587
R64147
Källén - BZDs, 2013 Pes equinovarus early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: Not specified 0.96 [0.31;2.24] 5/2,537   -/1,575,847 - 2,537
ref
S15535
R63831
Czeizel - Diazepam, 2003 Clubfoot 1st trimester case control unexposed (general population or NOS) Adjustment: Yes BZD Coexposure: Yes (with psychiatric (ATD and/or psychotropics) medications) Matched 1.00 [0.70;1.60] -/-   2,429/- - -
ref
Total 3 studies 1.00 [0.69;1.45] 1,678 3,517
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière - Clonazepam (Other indications), 2019Blotière - Clonazepam, 2019 1 1.14[0.16; 8.12]1,6789804%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Källén - BZDs, 2013Källén - BZDs, 2013 0.96[0.31; 2.24]-2,53714%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: criticalROB reporting: moderate Czeizel - Diazepam, 2003Czeizel - Diazepam, 2003 1.00[0.70; 1.60]--82%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: criticalROB reporting: moderate Total (3 studies) I2 = 0% 1.00[0.69; 1.45]1,6783,5170.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Other indications;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.99[0.41; 2.40]1,6783,5170%NABlotière - Clonazepam (Other indications), 2019 Källén - BZDs, 2013 2 case control studiescase control studies 1.00[0.66; 1.51]-- -NACzeizel - Diazepam, 2003 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.00[0.69; 1.45]1,6783,5170%NABlotière - Clonazepam (Other indications), 2019 Källén - BZDs, 2013 Czeizel - Diazepam, 2003 3 Tags Adjustment   - No  - No 1.14[0.16; 8.12]1,678980 -NABlotière - Clonazepam (Other indications), 2019 1   - Yes  - Yes 0.99[0.68; 1.46]-2,5370%NAKällén - BZDs, 2013 Czeizel - Diazepam, 2003 2 BZD Coexposure   - No (among antiseizure medications)  - No (among antiseizure medications) 1.14[0.16; 8.12]1,678980 -NABlotière - Clonazepam (Other indications), 2019 1   - Not specified  - Not specified 0.96[0.36; 2.58]-2,537 -NAKällén - BZDs, 2013 1   - Yes (with psychiatric (ATD and/or p ...  - Yes (with psychiatric (ATD and/or psychotropics) medications) 1.00[0.66; 1.51]-- -NACzeizel - Diazepam, 2003 1 MatchedMatched 1.00[0.66; 1.51]-- -NACzeizel - Diazepam, 2003 1 All studiesAll studies 1.00[0.69; 1.45]1,6783,5170%NABlotière - Clonazepam (Other indications), 2019 Källén - BZDs, 2013 Czeizel - Diazepam, 2003 30.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.69; 1.45]4,0983,5170%NABlotière - Clonazepam (Other indications), 2019 Källén - BZDs, 2013 Czeizel - Diazepam, 2003 30.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Veroniki a (NMA) (Clobazam) (All indications) ...Veroniki a (NMA) (Clobazam) (All indications) (Club foot) Out of scale14.11[0.03; 355.50]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 Veroniki a (NMA) (Clonazepam) (All indication ...Veroniki a (NMA) (Clonazepam) (All indications) (Club foot) 4.03[0.46; 27.55]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT-9 metaPregmetaPreg 1.00[0.69; 1.45]0%3,517----Blotière - Clonazepam (Other indications), 2019 Källén - BZDs, 2013 Czeizel - Diazepam, 2003 30.510.01.0